Envista (NYSE:NVST) Price Target Raised to $29.00

Envista (NYSE:NVST) had its price objective boosted by JPMorgan Chase & Co. from $26.00 to $29.00 in a report published on Thursday,Benzinga reports. The firm currently has a neutral rating on the stock.

Other research analysts have also issued reports about the company. Robert W. Baird increased their price objective on Envista from $30.00 to $31.00 and gave the company an “outperform” rating in a research report on Thursday. UBS Group increased their price objective on Envista from $22.00 to $25.00 and gave the company a “neutral” rating in a research report on Tuesday, February 3rd. Weiss Ratings upgraded Envista from a “sell (d)” rating to a “hold (c-)” rating in a research report on Tuesday, February 17th. Stifel Nicolaus set a $31.00 price objective on Envista in a research report on Friday, February 6th. Finally, Leerink Partners set a $35.00 price objective on Envista and gave the company an “outperform” rating in a research report on Friday, February 6th. Six research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.83.

Envista Stock Down 0.1%

NYSE NVST opened at $24.27 on Thursday. The firm has a market cap of $3.95 billion, a PE ratio of 59.18, a price-to-earnings-growth ratio of 1.64 and a beta of 0.92. Envista has a one year low of $16.41 and a one year high of $30.42. The stock’s 50 day simple moving average is $26.53 and its 200 day simple moving average is $24.06. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.44 and a quick ratio of 2.04.

Envista (NYSE:NVST) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.05. The business had revenue of $705.50 million for the quarter, compared to analyst estimates of $680.04 million. Envista had a return on equity of 7.11% and a net margin of 2.41%.Envista’s revenue for the quarter was up 14.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.24 EPS. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. As a group, sell-side analysts forecast that Envista will post 1.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Envista news, SVP Mischa Reis sold 9,675 shares of the stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $30.00, for a total value of $290,250.00. Following the transaction, the senior vice president directly owned 32,382 shares in the company, valued at approximately $971,460. This trade represents a 23.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.99% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Farther Finance Advisors LLC lifted its stake in shares of Envista by 317.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,349 shares of the company’s stock valued at $27,000 after purchasing an additional 1,026 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in shares of Envista by 16,711.1% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock valued at $31,000 after purchasing an additional 1,504 shares during the period. Allworth Financial LP lifted its stake in shares of Envista by 75.4% in the 4th quarter. Allworth Financial LP now owns 1,805 shares of the company’s stock valued at $39,000 after purchasing an additional 776 shares during the period. UMB Bank n.a. lifted its stake in shares of Envista by 46.1% in the 4th quarter. UMB Bank n.a. now owns 2,017 shares of the company’s stock valued at $44,000 after purchasing an additional 636 shares during the period. Finally, IFP Advisors Inc lifted its stake in shares of Envista by 102.9% in the 4th quarter. IFP Advisors Inc now owns 2,112 shares of the company’s stock valued at $46,000 after purchasing an additional 1,071 shares during the period.

Key Envista News

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Envista reported better-than-expected Q1 2026 results, with EPS of $0.36 versus the $0.31 consensus and revenue of $705.5 million versus $680.0 million expected, suggesting solid demand and execution. Envista (NYSE:NVST) Posts Better-Than-Expected Sales In Q1 CY2026
• Positive Sentiment: Management’s earnings transcript and presentation are likely reinforcing confidence in the turnaround and highlighting new growth drivers, which can support the stock if investors see improving fundamentals. Envista (NVST) Q1 2026 Earnings Transcript
• Positive Sentiment: Robert W. Baird raised its price target on Envista to $31 from $30 and kept an outperform rating, while JPMorgan lifted its target to $29 from $26, signaling improved analyst sentiment after the earnings beat.
• Positive Sentiment: Zacks highlighted Envista as a top long-term growth stock, which may help reinforce the market’s view that the company has attractive longer-term earnings potential. Why Envista (NVST) is a Top Growth Stock for the Long-Term
• Neutral Sentiment: Additional coverage on the Q1 earnings snapshot and key metrics is mostly informational, but it keeps the company in focus as investors assess whether the earnings beat is sustainable. Envista: Q1 Earnings Snapshot
• Neutral Sentiment: The stock still faces some caution because JPMorgan’s rating remained neutral despite the higher target, indicating analysts see upside but not a clear near-term rerating.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.